Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity.
about
Recent Advances in the Diagnosis and Treatment of Clostridium Difficile InfectionLaboratory diagnosis of bacterial gastroenteritisDiagnosis of Clostridium difficile Infections in ChildrenProcalcitonin levels associate with severity of Clostridium difficile infectionCost and Impact on Patient Length of Stay of Rapid Molecular Testing for Clostridium difficileEvaluation of Xpert C. difficile, BD MAX Cdiff, IMDx C. difficile for Abbott m2000, and Illumigene C. difficile Assays for Direct Detection of Toxigenic Clostridium difficile in Stool Specimens.Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era.Elevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults.Evaluation of a new automated homogeneous PCR assay, GenomEra C. difficile, for rapid detection of Toxigenic Clostridium difficile in fecal specimens.Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infectionMolecular methods in the diagnosis of Clostridium difficile infections: an update.Diagnosis of Clostridium difficile infection: the molecular approach.Optimizing the diagnostic testing of Clostridium difficile infection.Clostridium difficile PCR Cycle Threshold Predicts Free Toxin.Point-Counterpoint: What Is the Optimal Approach for Detection of Clostridium difficile Infection?Diagnosis and outcome of Clostridium difficile infection by toxin enzyme immunoassay and polymerase chain reaction in an island population.Hospitalized Patients with Cirrhosis Should Be Screened for Clostridium difficile Colitis.Reverse transcription polymerase chain reaction-based method for selectively detecting vegetative cells of toxigenic Clostridium difficile.Evaluation of Copan FecalSwab as Specimen Type for Use in Xpert C. difficile Assay.Diagnosing Clostridium difficile-associated diarrhea using enzyme immunoassay: the clinical significance of toxin negativity in glutamate dehydrogenase-positive patientsReply to Planche et al.Laboratory diagnosis of Clostridium difficile infections: there is light at the end of the colon.The never-ending struggle with laboratory testing for Clostridium difficile infection.Effect of nucleic acid amplification testing on population-based incidence rates of Clostridium difficile infection.Can a toxin gene NAAT be used to predict toxin EIA and the severity of Clostridium difficile infection?NAAT quantitation as predictor of toxin presence in Clostridium difficile infection.Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
P2860
Q26766112-AC32EDA7-D4D8-4C41-B004-9E6C1060FC48Q27027754-F19DF4F8-FE93-4D85-B746-460910D2808DQ28075324-5F1EEF99-4498-43CE-939A-3724AA35FD6AQ34625689-33DE4B25-9127-413E-9525-0C1D87917BF0Q34726112-F3F41E89-CCFE-4BBD-A6D7-99FB881FC592Q36465447-2A0AC948-5E47-435F-BC8F-CF6A497E5EADQ37035829-0A23F370-DA95-44C5-8877-9B6ED2E05659Q37103258-DD542FC6-0605-48C0-8E7C-07CCD302879DQ37109212-CD4893A4-766F-484D-98ED-C94AE3AB5F8CQ37125031-F180F56E-7043-42B6-9491-7DDDE159F8A6Q37293591-CCA8BDF7-BBED-48B4-81CA-0D589121030CQ38142247-447AF265-01EE-4124-AF66-E66DAEA4A340Q38165197-AFABCFAD-A591-4174-A4D4-935E4A182A9EQ38909959-FD0D844F-5050-4E6F-89A9-C36F80AAD9DFQ40172171-6EEC5F44-4861-4B20-A3ED-ECE0BF359F11Q40375743-97BD50AD-3DA8-485A-B535-728E17410008Q40582745-2F1AFA1A-A1C6-4208-990F-19DEDFB3A2BDQ40926881-0A23517C-BB49-49FF-BBB4-C36CC29F440DQ42200813-A046CE58-D44E-41C3-84B4-8766C1DC3743Q42267808-AE760923-3C0A-4714-96F6-110DE7549A57Q42744751-63B89524-2F98-4DF4-9BBB-8C2142ED392CQ43109733-C7D7265D-3F41-4EE2-8AC4-05A711A5EF28Q44088970-BC8D1C54-6ACF-4E55-9F6D-9345F98A91FDQ46203403-FB22E03F-3E01-48DB-AA61-FFDCFB5D5813Q46746593-D511875D-74DD-4D1D-9D81-25053C32DE13Q47134307-8F9AC10C-26B0-47BB-9F5F-3C571B0F4266Q47577224-60B60C4B-AADA-4A3C-9E1A-3B0D228AA88FQ56225357-92B859D8-10A3-4ADC-9AD6-78EFE2D49627
P2860
Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Performance of Clostridium dif ...... d by patient disease severity.
@ast
Performance of Clostridium dif ...... d by patient disease severity.
@en
type
label
Performance of Clostridium dif ...... d by patient disease severity.
@ast
Performance of Clostridium dif ...... d by patient disease severity.
@en
prefLabel
Performance of Clostridium dif ...... d by patient disease severity.
@ast
Performance of Clostridium dif ...... d by patient disease severity.
@en
P2093
P2860
P356
P1476
Performance of Clostridium dif ...... d by patient disease severity.
@en
P2093
Daniel Z Uslan
Romney M Humphries
Zachary Rubin
P2860
P304
P356
10.1128/JCM.02970-12
P407
P577
2012-12-26T00:00:00Z